XENE insider trading
NasdaqGM HealthcareXenon Pharmaceuticals Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Company website: www.xenon-pharma.com
XENE insider activity at a glance
FilingIQ has scored 459 insider transactions for XENE since Jan 7, 2015. The most recent filing in our index is dated May 12, 2026.
Across the full history, 53 open-market purchases
and 112 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on XENE insider trades is 57.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest XENE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding XENE
Frequently asked
- How many insider trades does FilingIQ track for XENE?
- FilingIQ tracks 459 Form 4 insider transactions for XENE (Xenon Pharmaceuticals Inc.), covering filings from Jan 7, 2015 onwards. 40 of those were filed in the last 90 days.
- Are XENE insiders net buyers or net sellers?
- Across the full Form 4 history for XENE, 53 transactions (12%) were open-market purchases and 112 (24%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does XENE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is XENE in?
- Xenon Pharmaceuticals Inc. (XENE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.36B.
Methodology & sources
Every XENE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.